Detalhe da pesquisa
1.
Current recommendations and recent progress in endometrial cancer.
CA Cancer J Clin
; 69(4): 258-279, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31074865
2.
Validation of the RSClin risk calculator in the National Cancer Data Base.
Cancer
; 130(8): 1210-1220, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38146744
3.
Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.
Gynecol Oncol
; 183: 103-114, 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38593674
4.
Tumor board presentation of a woman with metastatic, hormone receptor-positive, mismatch repair-deficient endometrial cancer.
CA Cancer J Clin
; 72(2): 102-111, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35077576
5.
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
; 397(10271): 281-292, 2021 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33485453
6.
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
N Engl J Med
; 381(25): 2403-2415, 2019 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562800
7.
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Gynecol Oncol
; 164(2): 278-287, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34930617
8.
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Gynecol Oncol
; 164(2): 245-253, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34906376
9.
Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients.
Cancer
; 127(2): 300-309, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33079393
10.
A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance).
Cancer
; 127(2): 291-299, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33079411
11.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
N Engl J Med
; 379(2): 122-137, 2018 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29863451
12.
Racial disparities in survival outcomes among breast cancer patients by molecular subtypes.
Breast Cancer Res Treat
; 185(3): 841-849, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33111220
13.
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
Gynecol Oncol
; 162(2): 375-381, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34112513
14.
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
Breast Cancer Res Treat
; 181(2): 347-359, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32274665
15.
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
Breast Cancer Res Treat
; 181(3): 623-633, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32378051
16.
Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations.
Gynecol Oncol
; 158(3): 531-537, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32641238
17.
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
Gynecol Oncol
; 158(3): 640-645, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32513564
18.
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Lancet Oncol
; 20(5): 636-648, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30948273
19.
Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
Breast Cancer Res
; 21(1): 82, 2019 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31340854
20.
Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer.
Int J Gynecol Cancer
; 29(2): 357-364, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30683758